Portal de Periódicos da CAPES

Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?

2016; Nature Portfolio; Volume: 13; Issue: 8 Linguagem: Inglês

10.1038/nrclinonc.2016.30

1759-4782

M. Bernstein, Sunil Krishnan, James W. Hodge, Joe Y. Chang,

Lung Cancer Diagnosis and Treatment

Substantial interest exists in the effects of immunotherapy; however, radiation therapy also has the potential to stimulate an antitumour immune response. In this Perspectives, the authors describe the rationale for combining immunotherapy with stereotactic ablative radiotherapy based on the available clinical data, and provide recommendations for the future testing of approaches using this combination of treatments. Conventional radiotherapy, in addition to its well-established tumoricidal effects, can also activate the host immune system. Radiation therapy modulates tumour phenotypes, enhances antigen presentation and tumour immunogenicity, increases production of cytokines and alters the tumour microenvironment, enabling destruction of the tumour by the immune system. Investigating the combination of radiotherapy with immunotherapeutic agents, which also promote the host antitumour immune response is, therefore, a logical progression. As the spectrum of clinical use of stereotactic radiotherapy continues to broaden, the question arose as to whether the ablative radiation doses used can also stimulate immune responses and, if so, whether we can amplify these effects by combining immunotherapy and stereotactic ablative radiotherapy (SABR). In this Perspectives article, we explore the preclinical and clinical evidence supporting activation of the immune system following SABR. We then examine studies that provide data on the effectiveness of combining these two techniques — immunotherapy and SABR — in an approach that we have termed 'ISABR'. Lastly, we provide general guiding principles for the development of future clinical trials to investigate the efficacy of ISABR in the hope of generating further interest in these exciting developments.